Physician profile
Nabil Abdo
NPI 1629226089
$2,099.82
in general payments reported to CMS, 2019-2025
23 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $511 · 2021: $133 · 2024: $48.16 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $330.70 | 2019-2025 | Farxiga |
| Pfizer INC. | $267.74 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.37 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $183.69 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $113.31 | 2019-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $102.93 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $73.74 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $71.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.98 | 2020 | |
| Tris Pharma INC | $39.38 | 2019-2020 | |
| Allergan, INC. | $36.67 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $34.76 | 2019-2020 | |
| Glaxosmithkline, LLC. | $33.37 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.99 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $30.21 | 2024-2025 | Gvoke Hypopen |
| Abbott Laboratories | $29.40 | 2025 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $22.70 | 2020 | |
| Abbvie INC. | $18.00 | 2025 | |
| Sumitomo Pharma America, INC. | $17.14 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $17.06 | 2019 | |
| Avvisto Therapeutics, LLC | $14.02 | 2025 | Cycloset |
| Dexcom, INC. | $13.55 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Abdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.